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ABSTRACT
Background: Reported benefits of maternal nutrition supplements
commenced during pregnancy in low-resource populations have
typically been quite limited.
Objectives: This study tested the effects on newborn size, especially
length, of commencing nutrition supplements for women in low-
resource populations ≥3 mo before conception (Arm 1), compared
with the same supplement commenced late in the first trimester of
pregnancy (Arm 2) or not at all (control Arm 3).
Methods: Women First was a 3-arm individualized randomized
controlled trial (RCT). The intervention was a lipid-based micronu-
trient supplement; a protein-energy supplement was also provided
if maternal body mass index (kg/m2) was <20 or gestational
weight gain was less than recommendations. Study sites were
in rural locations of the Democratic Republic of the Congo
(DRC), Guatemala, India, and Pakistan. The primary outcome was
length-for-age z score (LAZ), with all anthropometry obtained
<48 h post delivery. Because gestational ages were unavailable
in DRC, outcomes were determined for all 4 sites from WHO
newborn standards (non-gestational-age-adjusted, NGAA) as well
as INTERGROWTH-21st fetal standards (3 sites, gestational age-
adjusted, GAA).
Results: A total of 7387 nonpregnant women were randomly
assigned, yielding 2451 births with NGAA primary outcomes and
1465 with GAA outcomes. Mean LAZ and other outcomes did not
differ between Arm 1 and Arm 2 using either NGAA or GAA. Mean
LAZ (NGAA) for Arm 1 was greater than for Arm 3 (effect size:
+0.19; 95% CI: 0.08, 0.30, P = 0.0008). For GAA outcomes, rates
of stunting and small-for-gestational-age were lower in Arm 1 than
in Arm 3 (RR: 0.69; 95% CI: 0.49, 0.98, P = 0.0361 and RR: 0.78;
95% CI: 0.70, 0.88, P < 0.001, respectively). Rates of preterm birth
did not differ among arms.
Conclusions: In low-resource populations, benefits on fetal growth–
related birth outcomes were derived from nutrition supplements
commenced before conception or late in the first trimester. This trial
was registered at clinicaltrials.gov as NCT01883193. Am J Clin
Nutr 2019;109:457–469.
Keywords: preconception, pregnancy, birth length, stunting, lipid
nutrient supplement
Introduction
Linear growth restriction continues to be a major public
health challenge globally for poor communities in low- and
middle-income countries (1–3). Stunting before 2 y of age is
prominent among the nutrition factors related to disease burden
and mortality in early childhood (4, 5). Longer-term associations
of early linear growth faltering include impairment of motor
development, cognition, educational and economic achievement,
chronic disease, and low offspring birth size (6). Fetal growth
restriction is another major predictor of adverse outcomes
beyond the neonatal period, including mortality, stunting, and
impaired neurodevelopment (7–10). Recognition of the unique
and compelling opportunities for optimizing the environment of
both the fetus and young child has given prominence to the
concept of “The First 1000 Days” (6, 11) and has prompted
Am J Clin Nutr 2019;109:457–469. Printed in USA. © 2019 American Society for Nutrition. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any
medium, provided the original work is properly cited. 457
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numerous trials directed either to early postnatal life or, by
means of improving maternal nutrition, to life during gestation.
The environmental factors underlying stunting and adverse birth
outcomes are undoubtedly complex and potentially synergistic,
but maternal undernutrition can clearly result in deficits of
nutrients required for physical growth. Trials of maternal
supplements, typically initiated during the second trimester of
gestation, consisting of iron and folate, multimicronutrients with
or without lipids, or protein-energy supplements, have frequently
had some positive effect on offspring birth size, including length.
However, the effect sizes of such maternal interventions have
typically been quite modest (12–15).
Advantages of initiating maternal nutrition supplements
before conception have been suggested, particularly to correct
both maternal underweight and micronutrient deficiencies before
conception (16–18). Evidence of a beneficial effect of improved
nutrition during the periconceptional period is supported by
animal and epigenetic studies (19, 20). Currently, however,
information is too limited to reach definitive conclusions
regarding the potential benefits to the offspring of prevention
or treatment of maternal undernutrition before conception in
resource-poor settings (18, 21–24).
To address this gap in knowledge, we undertook a trial
known as Women First. The broad goal of the trial was to
evaluate the potential benefits on birth outcomes of promoting
optimal maternal nutrition for ≥3 mo before conception (25).
We hypothesized that for women living in poor environments
with high rates of stunting, starting a comprehensive nutrition
supplement during the preconception period would result in
significantly greater newborn length than starting the same
intervention at the junction of the first and second trimesters or
not being provided this supplement at all. In addition, we report
here the impact of the intervention on other birth outcomes.
Methods
Study design
This was an individually randomized, nonmasked, multisite
controlled efficacy trial (NCT01883193, initial release 18 June
Women First Preconception Trial Study Group collaborators are listed at
the end of this article.
Supported by Bill &Melinda Gates Foundation grant OPP1055867 (KMH,
NFK) and Eunice Kennedy Shriver National Institute of Child Health and
Human Development and Office of Dietary Supplements, NIH grant U10 HD
076474 (NFK, KMH).
Supplemental Tables 1–8 are available from the “Supplementary data” link
in the online posting of the article and from the same link in the online table
of contents at https://academic.oup.com/ajcn/.
Address correspondence to NFK (e-mail: nancy.krebs@ucdenver.edu).
Abbreviations used: BMIAZ, BMI-for-age z score; CRL, crown-rump
length; DCC, Data Coordinating Center; DRC, Democratic Republic of the
Congo; GA, gestational age; GAA, gestational-age-adjusted; GN, Global
Network; HC, head circumference; HCAZ, HC-for-age z score; LAZ,
length-for-age z score; LBW, low birth weight; NGAA, non-gestational-age-
adjusted; PTB, preterm birth; RCT, randomized controlled trial; SGA, small-
for-gestational age; WAZ, weight-for-age z score; WLRAZ, weight to length
ratio-for-age z score.
Received June 12, 2018. Accepted for publication August 7, 2018.
First published online February 5, 2019; doi: https://doi.org/10.1093/
ajcn/nqy228.
2013) to determine the effect of a preconception nutrition
supplement on birth length and other anthropometry outcomes
at birth. The trial included 3 arms: one that started the
supplement ≥3 mo before conception and continued through
delivery (Arm 1); a second arm that started the same intervention
late in the first trimester (Arm 2); and a third that received
no nutrition supplements besides those self-administered or
prescribed through local health services (Arm 3).
The trial was conducted in rural or semirural locations
in the Democratic Republic of the Congo (DRC; Equateur),
Guatemala (Chimaltenango), India (Belagavi, North Karnataka),
and Pakistan (Thatta, Sindh Province). Each of these 4 sites is
a member of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development Global Network (GN)
for Women’s and Children’s Health Research. Trial participants
were recruited from a total of 53 GN clusters, which were
geographic catchment areas, each ofwhich has∼300 deliveries/y.
Communication between the investigators based at the University
of Colorado and study partners in the 4 sites was facilitated
by the Data Coordinating Center (DCC) at RTI International
(Durham, NC) and included monthly data monitoring reports and
conference calls and periodic site visits by the lead investigators
to review study progress, share strategies, and conduct refresher
training as needed.
Participants
Womenwere identified through theGNMaternal andNewborn
Health Registry (26), household surveys, local health centers,
word-of-mouth, and local advertising. Community sensitiza-
tion meetings were held to explain the study to prospective
participants and families. All women were screened for the
following inclusion criteria: age 16–35 y; parity 0–5, with site-
specific strategies to include nulliparous participants; no current
or planned contraceptive use; and expectation to conceive during
the following 18 mo. Consent of parous women was delayed until
≥2 mo postpartum. Women with a known history of obstetric
complications or those who were unwilling to deliver in hospital
were excluded (25). If an otherwise eligible woman had a
hemoglobin concentration of ≤8 g/dL at screening, enrollment
was delayed until successfully treated, if at all. No women
were excluded on the basis of height, weight, or BMI (kg/m2).
Diets were predominantly based on staple foods, including
grains and tubers, and were generally low in dietary diversity
(27).
Randomization
The DCC created the randomization scheme, centrally gener-
ating the allocation sequence for each site. To ensure geographic
balance, a permuted block design stratified by GN clusters was
used for assigning individual participants to a trial arm. The
allocation ratio was 1:1:1 within blocks which randomly varied
between sizes of 3, 6, or 9 for each site. Once the responsible
home visitor research assistant identified an eligible participant,
they received the random assignment generated by the site data
manager from the centralized computerized data management
system maintained by the DCC.
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Procedures
Intervention.
The nutrition intervention, termed Supplement 1, has been
described in detail in the published protocol (25) (Supplemental
Table 1). Briefly, it was a lipid-based micronutrient supplement
(Nutriset) and provided micronutrients, polyunsaturated fats in a
favorable balance, and modest quantities of protein and energy
(2.6 g protein and 118 kcal) (25, 28). For Arm 1, the duration of
the primary supplement was from the time of random assignment
until delivery; participants were required to be on the primary
supplement for≥3mo before conception. For Arm 2, the primary
supplement covered the second and third trimesters of pregnancy
and was also stopped at delivery. Participants in Arm 3 were not
provided any nutrition supplement by the study.
In addition, in Arms 1 and 2, women were provided a second
daily lipid-based protein-energy supplement (termed Supplement
2, Supplemental Table 1) if they had a BMI <20 at any time
while receiving Supplement 1, or hadweight gain in the second or
third trimesters of pregnancy less than the Institute of Medicine’s
guidelines (29). If consumed completely, this supplement pro-
vided 300 kcal and 11 g protein (∼15% of energy) without
additional supplemental micronutrients (Nutriset). Supplement
2 was initiated before conception on the basis of BMI for
participants in Arm 1 as well as for gestational weight gain
during pregnancy (1.7–2.0 kg/mo). For Arm 2, Supplement 2
was started after the initiation of Supplement 1 when either
of the criteria became evident. For both arms, once initiated,
Supplement 2 was provided until delivery. Unlike the primary
supplement, high compliance was not required for the second
supplement because of our intention to minimize reduction in
habitual food intake and for participants to consume a quantity
“to appetite.” Recipients were encouraged to consume ≥50% of
the protein-energy supplement (Supplement 2) on a daily basis.
Participants in Arms 1 and 2 were cautioned not to take other
micronutrient supplements or fortified food products while taking
the trial supplements.
Home visits and compliance.
Participants in all 3 arms were visited by the home visitor
research assistants every 2 wk to record interim health history
and to administer a urine pregnancy test. The pregnancy testing
was combined with calendar records of menses to ascertain last
menstrual period and to guide the timing of ultrasounds to be
obtained between 10 and 12 weeks of estimated gestation. For
Arms 1 and 2, these visits were also used to replenish the supply
of trial supplements. Compliance with use of supplements was
documented by inspection of calendars the women completed
daily and by collection of empty, partially eaten, and unused inter-
vention sachets. Compliance was calculated for Supplement 1 as
the total number of sachets fully eaten divided by the number of
days between starting Supplement 1 and delivery. Supplement 2
compliancewas calculated similarly; however, the numerator was
the total number of Supplement 2 sachets fully or partially eaten.
Anthropometry.
Maternal height and weight measurements were obtained at
enrollment, and maternal weight was obtained at ∼12 and 32
wks of gestation for all arms. Additionally, monthly weights were
obtained once Supplement 1 was initiated (e.g., at enrollment
for Arm 1 and after the 12 wk gestation measurement for
Arm 2). Newborn anthropometry was obtained within 48 h
of delivery (neonatal stadiometer, Ellard Instrumentation, Ltd;
seca 334 electronic scale and seca 201 measurement tape, seca
North America). All anthropometry was performed by trained
assessment teams who were not involved in the biweekly home
visits. Assessment teams were extensively trained by study
coordinators to use standardized anthropometric methods and
were certified before data collection. The assessment teams’
procedures were observed by study coordinators at each site on
a monthly basis and were recertified at least quarterly. Infant
recumbent length and weight measurements were obtained in
triplicate and entered into the database; the median value was
used for analysis.
Gestational age determination.
First trimester ultrasound crown-rump length (CRL) measure-
ments were obtained for participants at 3 of the sites, allowing
for newborn anthropometry to be adjusted for gestational age
(GA). In the DRC, ultrasonography was not possible owing
to the absence of equipment, trained personnel, and reliable
power sources at the initiation of the study. In addition, the
calendars and pregnancy testing were not reliably implemented
to determine women’s last menstrual period. Thus, plausible GA
determinations were not possible for this site.
Outcomes.
The primary outcome, newborn length-for-age z score (LAZ),
was based on length measurements obtained by the assessment
teams before 48 h of age. Secondary outcomes reported here
by arm and site include weight, head circumference (HC),
and BMI, and the respective z scores: weight-for-age (WAZ),
HC-for-age (HCAZ), and BMI-for-age (BMIAZ) z score (30)
Gestational-age-adjusted (GAA) outcomes were determined
based on INTERGROWTH-21st fetal growth charts (31). In
addition to GAA LAZ, WAZ, and HCAZ, further outcomes
included: instead of BMIAZ, weight to length ratio-for-age
z score (WLRAZ), the proportions of infants with z scores
< −1 and < −2, low birth weight (LBW, <2500 g), small-for-
gestational age (SGA), and preterm birth (PTB).
Assessment of adverse events and safety monitoring.
Adverse events were monitored continuously as per protocol
(25) and reported to the overall study principal investigators
and the DCC within 48 h for all deaths and within 7 d for
other adverse events, including adverse pregnancy outcomes,
adverse neonatal events, hospitalizations, and allergic reactions.
A federally constituted Data Monitoring Committee reviewed
the study progress for safety, trial progress, data completion,
supplement compliance, and protocol violations twice yearly.
Ethics
The project was approved by the Colorado Multiple Institu-
tional Review Board, University of Colorado, the local and/or
national ethics committees for each of the 4 sites (registered with
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the US Office of Human Research Protection and with Federal-
wide Assurance in place), and the DCC. Written informed
consent was obtained from all participants. The study protocol
is available online (25).
Statistical methods
Sample size determination was based on testing 2 co-primary
hypotheses (comparison of Arm 1 with Arm 2 and Arm 1 with
Arm 3), for the primary outcome of LAZ at birth. The sample
size was based on also having 80% power within each site and
maintaining a study-wide Type I error rate of 0.05 across all
planned primary hypothesis tests (2 tests at each of 4 sites, for
a total of 8 tests). Thus, an α-level of 0.00625 for single-site
outcomes was specified to account for the 8 planned primary
comparisons. Assuming an α-level of 0.00625, a 2-sided test,
and an SD of 1.0 for the primary outcome, 192 evaluable women
per arm in each site were needed to detect an effect size of 0.37
with 80% power. To account for 20% attrition during pregnancy
required that 240 women per arm enter Phase 2 (pregnancy)
within each site. The assumption that 50% of women randomly
assigned at Phase 1 would get pregnant and move to Phase 2
required 480 women per arm to be enrolled in each site. Given
192 evaluable women per arm in each site for a total of 768
women per arm over all 4 sites, an α-level of 0.025 for each
primary hypothesis test across all sites would allow detection of
an effect size of 0.18with 90% power for each pooled comparison
of Arm 1 with Arm 2 and Arm 1 with Arm 3.
For the primary and secondary outcomes, newborn LAZ,
WAZ, HCAZ, and BMIZ were based on the WHO Child
Growth Standards (30), which account for infant sex and age
at measurement but are not adjusted for GA at delivery. Owing
to the lack of GA determinations in the DRC, we applied these
standards to all births in all sites in the same manner across
the 3 arms. Rates of LBW were also determined for the 4-
site data set. In addition, for the 3 sites with GA determination
(Guatemala, India, Pakistan), the INTERGROWTH-21st fetal
growth standards were also applied to birth measurements and
binary outcomes (31). These GAA analyses are a post hoc
exploration, with P values provided for descriptive purposes.
We assessed the study outcomes using a modified intention-
to-treat approach. The overall treatment effect and pairwise
comparisons for the primary outcome and continuous secondary
outcomes were obtained from linear models for the outcome of
interest. Model-generated measures of effect size with 95% CIs
and P values were adjusted for site and cluster-nested within
site. For binary secondary outcomes, generalized linear models
with generalized estimating equations were utilized to calculate
RRs with 95% CIs and P values after adjusting for site while
controlling for cluster correlations. The comparisons of Arm 1
with Arm 2 and Arm 1 with Arm 3 were prespecified in the
protocol. The comparison of Arm 2 with Arm 3, also presented
in this article, is a post hoc comparison. P values from chi-square
tests for categorical variables and ANOVA analysis of means
were calculated to assess differences between maternal baseline
characteristics by treatment arm. In addition, for the primary
outcome, we investigated potential confounding by baseline
maternal factors by first assessing differences in the maternal
factors by treatment arm and then adjusting the aforementioned
models for any factor which varied by treatment at an α-level
of 0.10. These maternal factors included age, parity, education,
BMI, height, and socioeconomic status.
As a statistical check to ensure that evaluating only a subset
of those randomly assigned (women who became pregnant and
delivered a live birth, with birth length evaluated) was not
unexpectedly skewing the results, we constructed a composite
binary secondary outcome that was evaluated alongside the
primary outcome. Among the randomly assigned women who
became pregnant, this outcome is defined as live birth free of
growth failure. Specifically, the outcome compared women who
delivered a live birth with LAZ ≥−1 to all other women who
became pregnant (i.e., delivered a live birth with LAZ <−1 and
womenwho did not deliver a live birth due tomedical termination
of pregnancy, miscarriage, stillbirth, and intrapartum death).
Womenwithout birth outcome data, includingwomen (all 3 arms)
who became pregnant too soon (i.e., enrolled in the study for
<3 mo before conception), were excluded from this analysis. For
this composite outcome, P values for the overall treatment effect
and pairwise comparisons were obtained from a generalized
estimating equation model adjusting for country and controlling
for cluster correlations. All analyses were performed by the DCC
using SAS/STAT software version 9.4 (SAS Institute).
Results
Participant flow and characteristics
Between December, 2013 and October, 2014, 12,551 women
were screened; 7686 (61.2%) were determined to be eligible
for the trial. Of these, 7376 (96.0%) consented, enrolled, and
were randomly assigned to 1 of the 3 study arms (Figure 1). In
addition, 11 women who were subsequently found to be outside
the inclusionary age range also consented and were enrolled for
a total of 7387 randomly assigned women (Figure 1). Fifty-six
percent (n = 4136) of those randomly assigned exited the
study in Phase 1 (preconception) (Figure 1). Prominent among
reasons for exiting were conception before 3 mo post–random
assignment (n = 1261), especially in Pakistan and India; no
longer wanted to participate (n = 773), primarily in Guatemala;
and had not conceived by the time the target sample size was
reached [i.e., completion of Phase 1 (n = 1572)] (Figure 1). An
additional 88 women exited the study after becoming pregnant.
As such, the delivery outcome was obtained for 3163 of 3251
(97.2%) eligible pregnancies, which included 25 multiple births,
for a total of 3188 infants.
There were 520 miscarriages or medical terminations of
pregnancy before 20 weeks of gestation (15.0% Arm 1; 16.7%
Arm 2; 17.2%Arm 3) (Figure 1). Eighty-two stillbirths (≥20 wk)
accounted for 2–3% of births across each arm. Of the 2586 live
births, 2459 (95.1%) had newborn measurements within 48 h of
delivery; 2451 (99.7%) had z scores within the biologically plau-
sible range according toWHO standards and were included in the
primary analysis. Among live births, 68 newborns died within 48
h of birth; of these newborns, 30 were measured before death.
Sixty percent of those with newborn primary outcome mea-
surements (n = 1465) also had CRL ultrasound measurements
between 6 weeks, 0 days and 13 weeks, 6 days of gestation and
were available for analysis, including 85.8% from India, 80.3%
from Guatemala, 68.5% from Pakistan, and none from DRC.
Numbers were equally distributed among arms. Mean ± SD GA
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/109/2/457/5307124 by Thom
as Jefferson U
niversity user on 25 February 2019
Preconception maternal nutrition 461
FIGURE 1 CONSORT diagram. Overall screening, random assignment, and obtainment of primary outcome by treatment arm. 1Percentage of those
randomly assigned. Excludes women who became pregnant <3 mo into the study. The women who had eligible pregnancies may have had delivery data
obtained or they may have exited the study before delivery. 2Primary outcome was obtained for live newborns with 3 length measurements taken within 48
h of delivery. Among women, primary outcome obtained from ≥1 infants of the woman. 3LAZ for birth length, based on actual birth length measured by 48
h of age, calculated using the expanded tables of the Child Growth Standards published by the WHO (30) that provide scores by day of measurement. The
same standards were used to calculate the weight-for-age, head circumference-for-age, and BMI-for age z scores (WAZ, HCAZ, and BMIAZ). 4GA at birth is
defined as the age at the time of the ultrasound based on the ultrasound plus time until birth if the ultrasound was done between 6 wk + 0 d and 13 wk + 6
d and the GA at birth was between 24 wk + 0 d and 42 wk + 6 d. If the ultrasound was not conducted during the GA previously mentioned, then the GA at
birth is missing. 5LAZ, WAZ, HCAZ, and weight to length-ratio-for age (WLRAZ) z scores and percentiles based on measurements within 48 h of delivery
are calculated using the INTERGROWTH-21st International Standards for Newborn Size (32) and International Standards for Newborn Size for Very Preterm
Infants (33), which provide z scores by sex and GA at birth for infants between 33 wk + 0 d and 42 wk + 6 d GA at birth and between 24 wk + 0 d and 32
wk + 6 d GA at birth, respectively. CONSORT, Consolidated Standards of Reporting Trials; GA, gestational age; LAZ, length-for-age z score; MTP, medical
termination of pregnancy.
at the time of the ultrasound measurements was 11.73 ± 1.13 wk
with minimal differences between arms and with a slightly higher
mean GA of 12.2 wk for India.
Baseline anthropometric characteristics of all women ran-
domly assigned have been reported previously (34). For women
who had primary outcome data collected, these and other
characteristics are given by site in Table 1. The only baseline
difference between those with a primary outcome and the entire
randomly assigned group was for parity: 20.4% and 27.5% were
nulliparous, respectively (data not shown).
Overall baseline characteristics by arm among women who
had the primary outcome obtained differed only in terms of
maternal education, with a higher percentage of women in Arm
1 having no formal education (P = 0.0081, Table 2).
Compliance, protein-energy supplement use, and maternal
weight gain
The mean± SD length of exposure for Supplement 1 for Arm
1 during the preconception periodwas 37.3± 21.5 wk, withmean
compliance of 88% (i.e., for every 100 d of exposure women
consumed 88 sachets). During the first 12 wk of pregnancy,
compliance for this group was similar at 87.3% ± 16.1%. From
12 wk to delivery, exposure for Arm 1 was 27.2 ± 1.9 wk and
compliance was 84.2% ± 17.4%. Total length of exposure for
Arm 1 from enrollment to delivery was 76.6 ± 21.6 wk with
overall compliance of 87.2%± 13.2%. For Arm 2, total length of
exposure for Supplement 1 was 25.4 ± 3.2 wk, and compliance
was 84.3% ± 17.4%.
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TABLE 1 Baseline characteristics among women who had the primary outcome for newborns, by site1
Variable DRC Pak Ind Guat
Randomly assigned, n 1741 2015 1823 1808
Women who had a live birth, n 608 697 609 651
Women who had the primary
outcome obtained for a
newborn,2 n (%)
576 (94.7) 663 (95.1) 591 (97.0) 612 (94.0)
Maternal age, n (%)
<20 y 141 (24.5) 116 (17.5) 147 (24.9) 90 (14.7)
20–24 y 228 (39.6) 222 (33.5) 317 (53.6) 247 (40.4)
≥25 y 207 (35.9) 325 (49.0) 127 (21.5) 275 (44.9)
Height, cm 156.1 ± 6.2 152.4 ± 6.3 151.4 ± 5.7 145.5 ± 4.93
BMI, kg/m2
Mean ± SD 20.6 ± 2.6 19.7 ± 2.9 20.1 ± 3.4 25.4 ± 4.23
<20.0 253 (43.9) 381 (57.5) 327 (55.3) 39 (6.4)
<18.5 101 (17.5) 235 (35.4) 219 (37.1) 8 (1.3)
Maternal education, n (%)
No formal schooling 135 (23.4) 562 (84.8) 45 (7.6) 49 (8.0)
Primary 342 (59.4) 66 (10.0) 93 (15.7) 410 (67.0)
Secondary or more 99 (17.2) 35 (5.3) 453 (76.6) 153 (25.0)
Parity, n (%)
0 (nulliparous) 121 (21.0) 190 (28.7) 151 (25.5) 35 (5.7)
1 135 (23.4) 152 (22.9) 243 (41.1) 234 (38.2)
≥2 320 (55.6) 321 (48.4) 197 (33.3) 343 (56.0)
Tally of indicators of higher SES,4 n (%)
None (0 present) 308 (53.5) 19 (2.9) 0 (0.0) 0 (0.0)
1–2 present 260 (45.1) 302 (45.6) 58 (9.8) 73 (11.9)
3–4 present 8 (1.4) 241 (36.3) 376 (63.6) 366 (59.8)
5–6 present 0 (0.0) 101 (15.2) 157 (26.6) 173 (28.3)
1Values are n, n (%), or means ± SDs. DRC, Democratic Republic of the Congo; Guat, Guatemala; Ind, India; Pak, Pakistan; SES, socioeconomic status.
2Primary outcome obtained from ≥1 newborns of the woman.
3n = 611 for height and BMI in Guatemala.
4The SES tally provides the number of indicators available from the following list: electricity, improved water source, sanitation, man-made flooring,
improved cooking fuels, and household assets.
Supplement 2, the protein-energy supplement, was started
in >90% of the women in Arm 1 in DRC, India, and Pakistan,
and in 88–96% of the women in these sites for Arm 2 (after 12
weeks of gestation). Less than 10% of the women in Guatemala
for either Arm 1 or Arm 2 started Supplement 2. Mean overall
Supplement 2 compliance for both arms was 84%, with total
duration of exposure 55.4 ± 29.4 and 22.0 ± 5.8 wk for Arms
1 and 2, respectively.
From baseline (preconception) to 12 weeks of gestation, mean
± SD weight gain was greater for women in Arm 1 than for those
in both Arms 2 and 3: 0.8± 3.9 kg, 0.0± 3.8 kg, and 0.3± 3.7 kg,
respectively (P< 0.0010). BMI figures at 12 wk were 21.8± 3.8,
21.4 ± 3.8, and 21.6 ± 3.9, for Arms 1, 2, and 3, respectively
(P = 0.082). Change in weight from baseline to 32 wk was also
greater for Arm 1 than for the other 2 arms: 6.9± 4.5 kg, 6.4± 4.1
kg, and 6.2 ± 4.4 kg, respectively (P < 0.0015).
Newborn anthropometry
Analysis of non-GAA data.
For neither all sites combined nor for any individual site
was the LAZ for Arm 1 significantly greater than the LAZ for
Arm 2 (Table 3, Supplemental Tables 2–5). In Guatemala, the
mean LAZ for Arm 1 was lower than that of Arm 2 (−0.27,
P = 0.0044). The mean LAZ, however, was higher for Arm 1
than for Arm 3 for combined sites (P < 0.01) and for DRC
and Pakistan (P < 0.00625). A small positive effect size was
observed for India (+0.17, P = 0.1244). Post hoc comparison
of Arm 2 with Arm 3 also revealed a significantly higher LAZ
for combined sites and for Pakistan. The LAZ effect size for
Arm 1 compared with Arm 3 was low (<0.2) for combined sites
and in the moderate range (0.20–0.39) for DRC and Pakistan
(Supplemental Tables 2 and 3). Effect sizes for WAZ were the
same as or lower than for LAZ but followed the same pattern, with
both Arms 1 and 2 greater than Arm 3 (Table 3, Supplemental
Tables 2–5). Mean z scores for all anthropometric outcomes for
the non-GAA (NGAA) data are shown by site (Figure 2). The
incidence of LBW for combined sites trended lower in both
Arm 1 and Arm 2 compared with Arm 3, with an RR of 0.86
(95% CI: 0.75, 0.98, P = 0.0263) and 0.81 (95% CI: 0.70, 0.93,
P = 0.0038), respectively.
No differences between arms or sites were observed for
either HCAZ or BMIAZ (Table 3). The analysis of live births
free of growth failure, constructed as a statistical check of the
primary outcome, demonstrated patterns consistent with that of
the primary LAZ outcome: a significant treatment arm effect
(P = 0.0021) and a difference between Arm 1 and Arm 3
(P = 0.0009) and Arm 2 and Arm 3 (P = 0.0166).
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TABLE 2 Overall baseline characteristics among women who had the primary outcome for newborns, by treatment arm1
Variable Arm 1 (n = 802, 97.0%)2 Arm 2 (n = 835, 94.7%)2 Arm 3 (n = 805, 94.0%)2
Maternal age, n (%)
<20 y 154 (19.2) 184 (22.0) 156 (19.4)
20–24 y 352 (43.9) 339 (40.6) 323 (40.1)
≥25 y 296 (36.9) 312 (37.4) 326 (40.5)
Maternal education,∗ n (%)
No formal schooling 287 (35.8) 252 (30.2) 252 (31.3)
Primary 263 (32.8) 320 (38.3) 328 (40.7)
Secondary or more 252 (31.4) 263 (31.5) 225 (28.0)
Height, cm 151.4 ± 6.6 151.2 ± 7.13 151.2 ± 7.0
BMI, kg/m2
Mean ± SD 21.4 ± 4.0 21.4 ± 4.13 21.5 ± 3.9
<20.0 324 (40.4) 347 (41.6) 329 (40.9)
<18.5 189 (23.6) 196 (23.5) 178 (22.1)
Parity, n (%)
0 (nulliparous) 186 (23.2) 165 (19.8) 146 (18.1)
1 244 (30.4) 262 (31.4) 258 (32.0)
≥2 372 (46.4) 408 (48.9) 401 (49.8)
Tally of indicators of higher SES,4 n (%)
None (0 present) 107 (13.3) 111 (13.3) 109 (13.5)
1–2 present 240 (29.9) 234 (28.0) 219 (27.2)
3–4 present 313 (39.0) 345 (41.3) 333 (41.4)
5–6 present 142 (17.7) 145 (17.4) 144 (17.9)
1Values are n (%) or means ± SDs. Differences between treatment arms were assessed by chi-square tests and ANOVA. ∗Significant difference among
arms, P = 0.0081. SES, socioeconomic status.
2Primary outcome obtained from ≥1 live newborns of the woman.
3n = 834 for height and BMI in Arm 2.
4The SES tally provides the number of indicators available from the following list: electricity, improved water source, sanitation, man-made flooring,
improved cooking fuels, and household assets.
Given that baseline maternal education varied by treatment
arm, the same analyses were repeated adjusting for maternal
education. The results did not change in direction or magnitude
(data not shown). Similarly, a primary outcome sensitivity
analysis adjusted for other maternal factors, including age, parity,
and BMI, did not change the results. No important differences
were observed according to interpregnancy interval, season of
delivery, or mode of delivery among arms (data not shown).
TABLE 3 Combined sites (Democratic Republic of the Congo, Pakistan, India, and Guatemala): growth outcomes by treatment arm among live births with
length at birth; comparison of effect sizes and 95% CIs1
Arm 1 vs. 3 Arm 2 vs. 3 Arm 1 vs. 2
Variable
Arm 1
809 (96.8)2
Arm 2
838 (94.7)2
Arm 3
812 (93.9)2
Effect size
(95% CI) P value
Effect size
(95% CI) P value
Effect size
(95% CI) P value
Length, cm 47.56 ± 2.29 47.59 ± 2.11 47.24 ± 2.17
LAZ − 1.05 ± 1.22 − 1.02 ± 1.11 − 1.22 ± 1.14 0.19 (0.08, 0.30) 0.0008 0.20 (0.09, 0.31) 0.0004 − 0.01 (−0.12, 0.10) 0.87
Weight, g3 2800.1 ± 448.9 2802.7 ± 424.3 2751.6 ± 423.3
WAZ3 − 1.13 ± 1.06 − 1.12 ± 1.01 − 1.25 ± 1.01 0.14 (0.04, 0.24) 0.0054 0.13 (0.03, 0.23) 0.0095 0.01 (−0.09, 0.11) 0.83
BMI4 12.33 ± 1.28 12.35 ± 1.21 12.27 ± 1.18
BMIAZ4 − 0.93 ± 1.12 − 0.91 ± 1.06 − 0.97 ± 1.05 0.06 (−0.04, 0.17) 0.21 0.07 (−0.03, 0.17) 0.19 − 0.00 (−0.10, 0.10) 0.96
HC, cm5 33.21 ± 1.51 33.24 ± 1.42 33.18 ± 1.49
HCAZ5 − 0.79 ± 1.21 − 0.75 ± 1.14 − 0.82 ± 1.18 0.07 (−0.04, 0.18) 0.23 0.08 (−0.03, 0.19) 0.14 − 0.02 (−0.13, 0.09) 0.79
1P values and effect sizes with corresponding 95% CIs comparing mean LAZ, WAZ, BMIAZ, and HCAZ for pairwise comparisons obtained from linear models for the
outcome of interest, adjusted for country and cluster-nested within country. For the primary outcome of LAZ at birth, the comparisons of Arm 1 with Arm 2 and Arm 1 with Arm 3
were evaluated at a significance level of α = 0.025 when combining data from all sites. P values are also provided for the secondary analyses. Because these are exploratory
analyses, no correction for multiple comparisons has been made. Values are n (%), means ± SDs, or effect size (95% CI). BMIAZ, BMI-for-age z score; HC, head circumference;
HCAZ, HC-for-age z score; LAZ, length-for-age z score; WAZ, weight-for-age z score.
2The primary outcome is among those who completed the assessment visit <48 h after delivery and had length measurements obtained. z Scores were calculated using the
expanded tables of the Child Growth Standards published by the WHO (30) and are based on term infants. LAZ and WAZ are within the biologically plausible ranges according to
the WHO standards. Numbers in parentheses in the column headers are percentages of live births with birth length obtained <48 h of age.
3Weight and WAZ: n = 807, 836, and 808 for Arms 1, 2, and 3, respectively.
4BMI and BMIAZ: n = 804, 831, and 806 for Arms 1, 2, and 3, respectively.
5HC and HCAZ: n = 805, 832, and 806 for Arms 1, 2, and 3, respectively.
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GAA newborn anthropometry.
The lower sample size for each outcome compared with
corresponding numbers for the NGAA data also reflects the lower
numbers for each site who had CRL measurements (Table 4).
Across the 3 sites and all arms, when we subset to the infants
with GA available, adjustment for GA age resulted in 16–45%
higher (less negative) LAZ compared with the NGAA data. For
example, the overall mean LAZ for Arm 3 in the NGAA analysis
was−1.22, compared with−0.88 for the GAA data (Table 4). As
for the NGAA data, Arm 1 LAZ did not differ from LAZ for Arm
2. The Arm 1 compared with Arm 3 effect size was again positive
for combined sites (+0.20), for India (+0.23), and for Pakistan
(+0.35) (Figure 3).
Similarly to the continuous outcomes for GAA data, none
of the binary outcomes differed between Arm 1 and Arm 2
(Table 5). However, there was a reduction in RRs for stunting
(LAZ <−2) for combined sites (Table 5) and for both Pakistan
and India for Arm 1 compared with Arm 3, but not for Arm 2
compared with Arm 3. There were also reductions in RR for
wasting (WLRAZ<−2) for Arm 1 compared with Arm 3 but not
Arm 2 compared with Arm 3, for combined sites and for India.
Substantial reductions in RR for SGA were evident for Arm 1
compared with Arm 3, for combined sites and for both Pakistan
and India (Table 5, Supplemental Tables 6–8, and Figure 4).
A decrease in RR for SGA also occurred for Arm 2 compared
with Arm 3, for combined sites and for India but not for Pakistan.
No reductions in RRs were observed for Guatemala for any of
the aforementioned newborn anthropometric outcomes except
WAZ <−2 for Arm 2 compared with Arm 3. The deficits in
mean HCAZ were small in comparison with other outcomes; no
effects of the interventions on HCAZ were observed (Table 4,
Supplemental Tables 6–8).
For combined sites, the incidence of PTB by arm was 12.5%,
8.6%, and 11.5% (P = 0.0407) for Arm 1, Arm 2, and Arm
3, respectively, among all live newborns, and 11.7%, 7.4%,
and 9.4% (P = 0.0047) among live newborns with birth length
obtained, respectively (Table 5, Supplemental Tables 6–8). For
Guatemala, the incidence of PTB by arm was 11.3%, 6.5%,
and 8.0% (P = 0.1645) for Arm 1, Arm 2, and Arm 3,
respectively, among all live-born infants, and 10.3%, 5.1%, and
3.8% (P = 0.0123) among live-born infants with birth length
obtained, respectively. The apparent drop in Arm 3 was due to
not getting birth measurements on 8 of 14 (57%) of the preterm
live births in this group.
Discussion
The results of this 4-site trial add substantially to the
evidence that poor fetal growth, including linear growth, in
low-resource countries can be improved with maternal nutrition
supplementation. Specifically, the intervention initiated before
conception or late in the first trimester resulted in greater mean
birth size (LAZ, WAZ, WLRAZ) and improved rates of stunting,
underweight, wasting (WLRAZ < −2), and SGA in comparison
with the control arm. Moreover, these benefits are evident in
women who were selected without regard for anthropometric or
biochemical evidence of malnutrition other than exclusion for
severe anemia at baseline. Furthermore, overall improvements
in fetal growth occurred despite the wide heterogeneity of the
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FIGURE 2 Mean ± SEM length-, weight-, and BMI-for-age z scores for
each site by treatment arm for non-gestational-age-adjusted data. P values
comparing mean z scores for pairwise comparisons of the treatment effect
were obtained from linear models for the outcome of interest, adjusted for
cluster. Pairwise comparisons of treatment arms within an individual site are
evaluated at a significance level of α = 0.00625. ∗Mean length-for-age z score
for Arm 1 differs from Arm 3 in Pak (P= 0.0057) and in DRC (P= 0.0042).
∗∗Arm 1 differs from Arm 2 in Guat (P = 0.0044). Sample size for each arm
within a site ranged as follows: n = 183–199 (DRC), n = 201–236 (Pak),
n = 199–200 (Ind), and n = 189–216 (Guat). DRC, Democratic Republic of
the Congo; Guat, Guatemala; Ind, India; Pak, Pakistan.
participating sites. With the exception of Guatemala, the mean
effect sizes compare favorably with overall results of reported
maternal nutrition interventions with either multimicronutrients
alone, lipid-based nutrient supplement preparations, or a similar
lipid-based protein-energy supplement commencing in mid-
gestation (14, 15, 35–38). However, starting the supplement
before conception did not result in significantly greater newborn
LAZ than starting the same intervention late in the first
trimester.
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TABLE 4 Combined GAA sites (Pakistan, India, and Guatemala): continuous growth outcomes by treatment arm among live births with GA and length at
birth; comparison of effect sizes with 95% CIs1
Arm 1 vs. 3 Arm 2 vs. 3 Arm 1 vs. 2
Variable
Arm 1
(n = 489)2
Arm 2
(n = 517)
Arm 3
(n = 459)
Effect size
(95% CI) P value
Effect size
(95% CI) P value
Effect size
(95% CI) P value
Length, cm 47.57 ± 2.19 47.64 ± 2.36 47.31 ± 2.31
LAZ − 0.69 ± 0.97 − 0.69 ± 1.04 − 0.88 ± 1.04 0.20 (0.07, 0.33) 0.0027 0.19 (0.07, 0.32) 0.0029 0.00 (−0.12, 0.13) 0.95
Weight, g 2783.6 ± 441.5 2784.4 ± 438.8 2740.2 ± 408.7
WAZ − 0.90 ± 0.93 − 0.95 ± 0.94 − 1.06 ± 0.93 0.17 (0.06, 0.29) 0.0036 0.12 (0.00, 0.23) 0.0455 0.06 (−0.06, 0.17) 0.33
WLR3 5.85 ± 0.72 5.84 ± 0.71 5.79 ± 0.66
WLRAZ3 − 1.22 ± 1.34 − 1.31 ± 1.31 − 1.43 ± 1.31 0.22 (0.06, 0.38) 0.0081 0.14 (−0.02, 0.30) 0.10 0.08 (−0.08, 0.24) 0.30
HC, cm4 33.01 ± 1.42 33.05 ± 1.48 33.00 ± 1.49
HCAZ4 − 0.47 ± 1.03 − 0.47 ± 1.05 − 0.52 ± 1.08 0.06 (−0.08, 0.19) 0.40 0.06 (−0.07, 0.19) 0.37 0.00 (−0.13, 0.13) 0.96
1P values and effect sizes with corresponding 95% CIs comparing mean LAZ, WAZ, HCAZ, and WLRAZ for pairwise comparisons obtained from linear models for the
outcome of interest, adjusted for country and cluster-nested within country. Because these are exploratory analyses, no correction for multiple comparisons has been made. Values
are mean ± SD or effect size (95% CI). GA, gestational age; GAA, gestational-age adjusted; HC, head circumference; HCAZ, HC-for-age z score; LAZ, length-for-age z score;
WAZ, weight-for-age z score; WLR, weight to length ratio; WLRAZ, WLR-for-age z score.
2Number of participants with primary outcome and GA determined. The primary outcome is among those who completed the assessment visit <48 h after delivery and had
length measurements obtained. LAZ, WAZ, HCAZ, and WLRAZ calculated using the INTERGROWTH-21st Project standards which provide z scores by sex and GA at birth for
infants between 33 wk + 0 d and 42 wk + 6 d GA at birth (32) and between 24 wk + 0 d and 32 wks + 6 d GA at birth (33). GA at birth is defined as the GA at the time of the
ultrasound based on the ultrasound plus time until birth if the ultrasound was done between 6 wk + 0 d and 13 wk + 6 d and GA at birth was between 24 wk + 0 d and 42 wk + 6 d.
If the ultrasound was not conducted during this time, GA at birth was set to missing.
3WLR and WLRAZ: n = 484, 514, and 455 for Arms 1, 2, and 3, respectively.
4HC and HCAZ: n = 488, 516, and 459 for Arms 1, 2, and 3, respectively.
The RRs for binary outcomes and some of the effect sizes
for continuous variables reported here were not included in the
original proposal and should be regarded as exploratory. In this
context, however, there are informative differences illustrating
the heterogeneity between sites. Effect sizes for comparison
of LAZ between the preconception and control arms were
substantial in both Pakistan and DRC where they approached the
effect size hypothesized in the original proposal (25). A similar
pattern was evident for RRs of binary measures of linear growth,
especially for stunting (LAZ <−2) and also to a lesser degree
for impaired linear growth (LAZ <−1), which has predictive
value for postnatal growth (7, 39). Corresponding responses
to the intervention compared with controls were observed for
weight-related outcomes, both continuous and binary. SGA
was especially high in India, and substantial reductions in
RRs for both SGA and WLRAZ were associated with the
intervention, most notably with the preconception intervention
(Figure 3). Consistent with this, effects of the intervention on
LBW were also observed for the 4 sites combined (NGAA
data). In Guatemala, no positive outcomes were observed for
either continuous or binary variables for Arm 1 and Arm 3
comparisons.
The primary intervention for which we have detailed informa-
tion on compliance was similar to a widely used small-quantity
lipid-based nutrient supplement with modest protein and energy
content and micronutrient amounts appropriate for pregnancy
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FIGURE 3 Effect sizes and 95% CIs for pairwise comparisons of the difference in mean length-for-age z scores at birth by treatment arm, by site and
for combined sites. Effect sizes with corresponding 95% CIs obtained from linear model, adjusted for clusters. The combined site analysis is adjusted for
country and cluster-nested within country. GAA data (31) presented for all individual sites except for the DRC which is not adjusted for gestational age (30).
“All” represents combined data from the 3 sites with GAA data available (Pak, Ind, and Guat; n = 459–517 per arm). Sample size for each arm within a site
ranged as follows: n = 141–160 (Pak), n = 158–184 (Ind), n = 156–177 (Guat), and n = 183–199 (DRC). DRC, Democratic Republic of the Congo; GAA,
gestational-age adjusted; Guat, Guatemala; Ind, India; Pak, Pakistan.
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TABLE 5 Combined GAA sites (Pakistan, India, and Guatemala): binary growth outcomes by treatment arm among live births with GA and length at birth;
comparison of RRs with 95% CIs1
Arm 1 Arm 2 Arm 3 Arm 1 vs. 3 Arm 2 vs. 3 Arm 1 vs. 2
Variable (n = 489)2 (n = 517) (n = 459)
RR
(95% CI) P value
RR
(95% CI) P value
RR
(95% CI) P value
LAZ <−1 175 (35.8) 194 (37.5) 201 (43.8) 0.82 (0.72, 0.93) 0.0019 0.86 (0.75, 0.98) 0.0205 0.95 (0.81, 1.12) 0.57
LAZ <−2 49 (10.0) 57 (11.0) 65 (14.2) 0.69 (0.49, 0.98) 0.0361 0.78 (0.57, 1.07) 0.12 0.89 (0.64, 1.24) 0.48
WAZ <−2 62 (12.7) 59 (11.4) 79 (17.2) 0.71 (0.56, 0.90) 0.0049 0.66 (0.50, 0.85) 0.0017 1.08 (0.85, 1.38) 0.51
WLRAZ <−23 128 (26.4) 157 (30.5) 155 (34.1) 0.76 (0.65, 0.89) 0.0005 0.88 (0.76, 1.02) 0.09 0.87 (0.75, 1.00) 0.0435
HCAZ <−24 36 (7.4) 33 (6.4) 35 (7.6) 0.93 (0.62, 1.40) 0.73 0.83 (0.59, 1.18) 0.31 1.12 (0.71, 1.76) 0.63
SGA 161 (32.9) 185 (35.8) 188 (41.0) 0.78 (0.70, 0.88) <0.001 0.87 (0.78, 0.96) 0.0047 0.90 (0.79, 1.04) 0.15
LBW 118 (24.1) 119 (23.0) 125 (27.2) 0.86 (0.72, 1.04) 0.11 0.85 (0.70, 1.02) 0.08 1.02 (0.80, 1.29) 0.88
Incidence of PTB, all live 63 (12.5) 46 (8.6) 56 (11.5) 1.05 (0.79, 1.41) 0.73 0.74 (0.50, 1.09) 0.12 1.43 (1.08, 1.89) 0.0117
Incidence of PTB, with LAZ 57 (11.7) 38 (7.4) 43 (9.4) 1.18 (0.82, 1.71) 0.38 0.77 (0.50, 1.20) 0.25 1.52 (1.18, 1.97) 0.0014
1P values and RRs with corresponding 95% CIs comparing proportion of LAZ <−1, LAZ <−2, WAZ <−2, HCAZ <−2, WLRAZ <−2, SGA, and LBW for the pairwise
comparisons are obtained from generalized linear models with generalized estimating equations to estimate parameters while controlling for cluster correlations. Models are
adjusted for country. Because these are exploratory analyses, no correction for multiple comparisons has been made. Values are n (%) or RR (95% CI). GA, gestational age; GAA,
gestational-age adjusted; HCAZ, head circumference-for-age z score; LAZ, length-for-age z score; LBW, low birth weight; PTB, preterm birth; SGA, small-for-gestational-age;
WAZ, weight-for-age z score; WLRAZ, weight to length ratio-for-age z score.
2Number of participants with primary outcome and GA determined. The primary outcome is among those who completed the assessment visit <48 h after delivery and had
length measurements obtained. LAZ, WAZ, HCAZ, and WLRAZ were calculated using the INTERGROWTH-21st Project standards which provide z scores by sex and GA at birth
for infants between 33 wk + 0 d and 42 wk + 6 d GA at birth (32) and between 24 wk + 0 d and 32 wk + 6 d GA at birth (33). GA at birth is defined as the GA at the time of the
ultrasound based on the ultrasound plus time until birth if the ultrasound was done between 6 wk + 0 d and 13 wk + 6 d and GA at birth was between 24 wk + 0 d and 42 wk + 6 d.
If the ultrasound was not conducted during this time, GA at birth is set to missing.
3WLRAZ <−2: n = 484, 514, and 455 for Arms 1, 2, and 3, respectively.
4HCAZ <−2: n = 488, 516, and 459 for Arms 1, 2, and 3, respectively.
and lactation (28). An additional protein-energy supplement was
provided to women who were underweight or had low gestational
weight gain. The latter reason accounted for provision of the
second supplement to >90% of women in both Arms 1 and
2 (except for Guatemala) starting at some stage in the second
or third trimester and continuing until delivery. Participants
were encouraged to consume this second supplement but the
actual amount was left to the woman’s discretion in order to
minimize interference with consumption of the habitual diet.
That this guideline was effective for Arm 1 was indicated by
the lack of any difference in energy consumption from local
food between Arms 1 and 2 during the first trimester in a
random subsample (27). Despite provision of the protein-energy
supplement, the average gestational weight gain through 32 wk
remained low relative to international recommendations (40).
Both low prepregnancy weight and gestational weight gain<8 kg
have been associated with LBW and SGA rates, and these
factors may have been relevant to outcomes in the current trial
(22).
This trial coincided with growing interest in the potential
value of preventing or correcting maternal undernutrition before
conception (11, 18, 41). One trial of preconceptionmultimicronu-
trient maternal supplements conducted in Vietnam demonstrated
a modest improvement in iron stores but no impact on birth
outcomes (24). Results of an a priori secondary analysis from a
food-based intervention trial targeting a poor urban population
in India were consistent with an increase in birth weight if the
supplement was commenced ≥3 mo before conception. The
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FIGURE 4 RRs and 95% CIs for pairwise comparisons of SGA by treatment arm, by site, and for combined sites (31). RRs with corresponding 95% CIs
comparing proportions of SGA for the pairwise comparisons are obtained from generalized linear models with generalized estimating equations to estimate
parameters while controlling for cluster correlations. For combined data, models are adjusted for country. Women First newborn measurements based on those
with gestational age data. "All" comprised combined data from Pak, Ind, and Guat. Sample sizes for each arm within a site ranged as follows: n = 141–160
(Pak), n = 158–184 (Ind), n = 156–177 (Guat), and n = 459–517 (All). Guat, Guatemala; Ind, India; Pak, Pakistan; SGA, small for gestational age.
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results of that trial also differed by maternal prepregnancy weight
status, with no overall impact of the intervention on birth weight,
the primary outcome, but a significant interaction such that birth
weight, birth length, and rates of LBW were improved in women
with BMI >21.8 at baseline (21).
A major weakness of the trial was the inability to determine
GA in the DRC with the resultant loss of the sub-Saharan
African site for the GAA data. This loss detracted from
the global scope of the trial. Moreover, the DRC had the
most favorable Arm 1 compared with Arm 3 improvement
in mean LAZ based on the NGAA data. Subject numbers
were further reduced for GAA data, both combined and in the
other 3 sites, especially in Pakistan, due to failure to obtain a
first-trimester ultrasound in all participants. Final numbers for
this post hoc GAA analysis were thus well below those available
for the trial primary outcome analysis predicated on NGAA
LAZ at birth. Another factor adversely affecting effect sizes and
RRs for combined sites was the negative Arm 1 result for the
Guatemala site. We speculate that this outcome was attributable,
in part, to the high proportion of Arm 3 preterm infants who
did not have primary outcome measures. These losses were
for diverse reasons apparently unrelated to the trial. Support
for this explanation has been derived from disappearance of
the negative Arm 1 compared with Arm 3 results for LAZ for
Guatemala newborns delivered at term only (data not presented).
However, it remains disappointing and unexplained that there
was no indication of a positive effect on fetal linear growth
in this indigenous population with exceptionally high rates of
stunting but with a substantially lower proportion of maternal
underweight than in the other 3 sites (34). It is possible that
potential benefits of the Arm 1 intervention to the linear growth
of this population may be discernible in the next generation
[i.e., those born to the female infants in the current study (42)].
Primary reliance on participants’ reported consumption of the
supplements represents a potential weakness. This was mitigated
by the biweekly home visits which provided opportunities for
the field staff to work closely with mothers to identify palatable
ways to consume the supplements and frequently to observe
consumption.
Notable features of this trial included the diverse low-resource
sites in which it was conducted, in 4 countries across 3
continents. The participating women, who had wide differences
in diet, culture, socioeconomic status, and education, were not
selected on the basis of current evidence of undernutrition
except for at least temporary exclusion if hemoglobin was
<8 g/dL. The trial was unusual in testing the effects of a
relatively comprehensive combination of nutrition products (i.e.,
those containing micronutrients as well as a protein-energy
supplement). Finally, the trial is one of very few that have
addressed the huge potential challenge of preventing or correcting
undernutrition of both micronutrients and macronutrients in
females of reproductive age before conception.
In resource-poor rural or semirural populations in which
there is a high prevalence of stunting, fetal growth was
improved with maternal nutrition supplements commenced either
before conception or late in the first trimester and provided
to women irrespective of their own nutritional status. This
improvement was achieved without the support of nutrition
education and without any attention to other environmental
factors associated with impaired fetal and early postnatal growth.
Results for sites were heterogeneous with improvements in
newborn LAZ, the primary outcome, ranging from zero to more
than one-third of deficits. Results were more favorable than
most reported data for maternal nutrition supplements initiated
during pregnancy, which could be attributable to the timing
of the initiation of the supplements. Despite the trial’s failure
to achieve optimal maternal gestational weight gain and to
support its principal primary hypothesis, the results of data
analyses undertaken within a hypothesis-generating framework
suggest that further work is needed. Meanwhile, the results are
strongly supportive of strategies to improve inadequate nutrition
in women, commencing before conception or very early in
gestation.
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